Table 1.

Clinicopathologic Features of Primary Gall Bladder and Bile Duct Lymphomas.

Case/Sex	Age	Clinical presentation	Stones	Diagnosis	Regional node involvement	Pertinent studies
1/M	5	Cholecystitis	No	PTCL (PTLD)	Yes	CD2+, CD4+,CD8−, BF1+, CD56−, EBER−, TRG monoclonal
2/F	37	Cholecystitis	No	B-LBL	NA	CD79a+, PAX5+, CD10+, TdT+, CD20(focal)
3/M	37	GB mass HIV+	No	PEL, Extracavitary variant	No	PAX5+ (focal), MUM1+, EMA+, EBER+, HHV8+
*4/F	48	Obstructive jaundice	No	FL Grade 3B	No	CD20+, CD30+, CD43+ (focal), BCL2−, BCL6−, CD10−
5/M	51	Cholecystitis and GB mass, HIV+	No	PBL	NA	CD79a+, CD138+, MUM1+, CD10+(focal), EBER+
6/M	51	NA	NA	FL Grade 1– 2	No	CD20+, CD10+, BCL2+, BCL6+
7/M	51	Cholelithiasis	Yes	FL Grade 1– 2	Yes	CD20+, CD10+, BCL2+
8/M	65	Incidental cholecystectomy; colon resection for adenocarcinoma	No	MCL in situ	NA	CD20+, CD5−, CD43+, SOX11+, CYCLIN D1+, LAMBDA+ t(11;14)+
9/M	72	Cholecystitis	Yes	DLBCL	Yes	CD20+, CD10+, BCL2+, t(14;18)+
10/M	74	Cholelithiasis, h/o colon cancer	Yes	EMZL	NA	CD20+(focal), CD79a+, KAPPA+, CD43−, IGH monoclonal
11/F	74	Cholecystitis	No	DLBCL	NA	CD20+, CD10−, BCL6+, MUM1−, BCL2+
12/M	74	Cholecystitis	No	B-LBL	No	PAX5+, CD10+, CD99+, TdT+(focal), IGH monoclonal
13/M	75	Cholecystitis	Yes	DLBCL	NA	CD20+, CD10−, BCL6−, BCL2+
14/F	84	Cholecystitis	No	EMZL	NA	CD20+, CD79a+, KAPPA+ (focal), IGH monoclonal

^*case involving common hepatic duct, previously reported by Jho et al (32)

DLBCL – diffuse large B-cell lymphoma; EMZL – extranodal marginal zone lymphoma; FL – follicular lymphoma; GB – gall bladder; LBL – lymphoblastic lymphoma; MCL – mantle cell lymphoma; NA – not available; PBL – plasmablastic lymphoma; PEL – primary effusion lymphoma; PTCL – peripheral T-cell lymphoma; PTLD – post-transplantation lymphoproliferative disorder